Pharma Counterfeit Analytics 2025 and 2026 Outlook

How pharma counterfeit analytics evolved in 2025 and where it’s heading in 2026, with data, AI trends, and practical strategies for safer medicine supply chains.

Pharma Counterfeit Analytics in 2025 – Data, Risks and What to Expect in 2026

What pharma counterfeit analytics means

Pharma counterfeit analytics is the structured use of data, technology, and forensic methods to detect, quantify, and predict falsified and substandard medicines across the value chain.  

It turns disparate signals – from seizures and serialization data to online pharmacy patterns – into actionable intelligence for regulators, marketing authorization holders, and manufacturers.

Key insight: Pharma counterfeit analytics transforms scattered incident reports into a continuous, data-driven risk map for the global medicine supply chain.

Core components of pharma counterfeit analytics include:

- Incident and seizure data (law enforcement, customs, regulators)  

- Serialization and traceability data (e.g., DSCSA, EU‑FMD repositories)  

- Packaging and product authentication signals (marker-based and markerless)  

- Channel intelligence (wholesalers, pharmacies, HCP feedback, patients)  

- Digital and dark‑web monitoring (illegal online pharmacies, social media)  

Why counterfeit analytics matters for pharma

A significant share of medical products in low‑ and middle‑income countries is estimated to be substandard or falsified, which underlines the systemic nature of the problem.  

The counterfeit drug trade is valued at tens of billions of dollars annually, driven by sophisticated global networks and online distribution.

In 2025, several dynamics increased urgency:

- High‑profile seizures of counterfeit GLP‑1 weight‑loss injections and other high‑value therapies  

- Joint reports highlighting contaminated and falsified excipients as a systemic threat  

- Evidence that official alerts capture only a fraction of actual incidents due to under‑reporting

Key insight: Counterfeit analytics is now a core risk and compliance function tied directly to patient safety, brand equity, and regulatory trust – not a “nice to have.”

2025 snapshot: the state of pharma counterfeits

Scale and patterns in 2025

In 2025, counterfeit medicines did not decline; they evolved toward higher value molecules and more complex digital distribution models.  

Multiple sources confirmed a rise in sophisticated operations, particularly targeting high‑demand products and exploiting gaps in globalized supply chains.

Typical 2025 patterns included:

- Focus on GLP‑1 and metabolic drugs as the most attractive counterfeit targets  

- Increased use of e‑commerce, social media, and illegal online pharmacies for direct‑to‑consumer sales  

- Cross‑border, networked operations with industrial‑scale production facilities  

- Criminal exploitation of excipient supply chains and falsified labels or CoAs

Regulatory and enforcement agencies emphasized falsified bulk excipients, under‑regulated suppliers, and weak post‑market surveillance as critical risks.  

At the same time, official alert systems were acknowledged to represent only a small proportion of true incidents worldwide.

Regulatory and enforcement context

In regulated markets, analytics are increasingly tied to formal frameworks:

- The EU Falsified Medicines Directive (FMD) and similar frameworks have introduced end‑to‑end verification in the legal supply chain.  

- In the U.S., DSCSA enforcement is driving unit‑level traceability and making untraceable product flows more visible in analytics systems.

Multi‑agency operations and seizures demonstrated the value of integrated seizure and risk data for trend analysis.  

However, analytics still struggle with blind spots in informal markets, fragmented reporting systems, and limited laboratory capacity in some regions.

Section summary: 2025 was marked by higher sophistication of counterfeiters, stronger regulation in formal channels, and a visible shift toward risk‑based, data‑driven enforcement – but global visibility remains incomplete.

Key components of pharma counterfeit analytics

1. Incident and seizure analytics

Incident analytics aggregate data from:

• National medicines regulators and pharmacovigilance systems  

• Customs and border agencies  

• Police and multi‑agency operations  

• Global and regional medical product alerts  

• Analysts look for:

• Product clusters (e.g., GLP‑1s, oncology, antibiotics)  

• Geographical hot spots and route patterns  

• Shifts from physical marketplaces to online ecosystems  

Key insight: Seizure and alert data are imperfect proxies, but time‑series analytics over multi‑source enforcement data remain one of the fastest ways to detect emerging counterfeit waves.

2. Serialization and traceability data

Serialization systems (EU‑FMD, DSCSA, and national frameworks) provide high‑granularity data on pack movement and verification events.  

Analytics use this information to detect anomalies such as duplicate serials, unexpected movement paths, and verification failures at endpoints.

Common use cases:

- Confirming whether a product is within the legitimate supply chain  

- Detecting diversion and parallel trade beyond approved routes  

- Supporting targeted recalls by pinpointing affected serial ranges  

For Quality and Regulatory leaders, this data becomes an extension of the QMS: it supports deviation investigations, CAPA decisions, and recall scope definition.

3. Channel, digital, and patient intelligence

Modern counterfeit analytics also incorporates:

• Wholesaler and distributor anomaly reports  

• Pharmacy and HCP feedback on suspect products  

• Patient complaints and adverse events with authenticity concerns  

• Web and social‑media monitoring of illegal online offers and suspicious marketplaces  

This broader lens helps Brand Protection and Commercial teams understand where leakage points are and how counterfeit activity interacts with pricing and access.

Anti‑counterfeit technologies and the analytics layer

Market growth and technology mix in 2025

The global anti‑counterfeit pharmaceutical packaging market in 2025 is estimated in the hundreds of billions of dollars and is projected to grow at a high single‑digit CAGR into the 2030s.  

Growth is driven by stricter regulation, rising incident rates, and the shift toward serialized, tamper‑evident, and track‑and‑trace solutions.

Key authentication and tracking technologies include:

- Mass serialization and 2D codes  

- RFID and NFC tags  

- Tamper‑evident closures and seals  

- Overt and covert security inks and features  

- Digital verification apps and cloud platforms  

Key insight: The real value is no longer in the label alone, but in the analytics system that turns every verification scan into a datapoint for risk detection and market transparency.

Marker‑based vs markerless, material‑level analytics

Traditional systems rely on external markers (codes, labels, chips), which can be removed, copied, or cloned, and often create a recurring “per‑unit tax” on packaging.  

Emerging markerless approaches analyze the unique micro‑structure of the material itself, turning the product surface into a persistent, difficult‑to‑replicate identifier.

Material‑level analytics offer:

- No change to packaging or aesthetics (“aesthetics of absence”)  

- Reduced OPEX by shifting from consumables to CAPEX infrastructure  

- Higher resilience against label counterfeiting or tag removal  

For highly regulated segments such as pharmaceuticals, a combined approach—serialization, tamper evidence, and surface‑based material analytics—creates a multilayered barrier.  

It also produces richer data for analytics, improving recall optimization, market investigations, and CAPA effectiveness.

Section summary: Anti‑counterfeit technology is moving from “add more labels” to “engineer the data layer,” where markerless and material‑level solutions complement classic packaging security.

How AI and advanced analytics changed the game in 2025

From descriptive to predictive analytics

By 2025, leading organizations began moving from backward‑looking incident counting toward predictive and prescriptive analytics.  

They combined enforcement data, market demand signals, pricing anomalies, and web intelligence to anticipate where counterfeiting was most likely to surge next.

Practical AI applications included:

- Anomaly detection in serialization, shipment, and verification data  

- Image‑based verification of packaging and product surfaces  

- Natural language processing over takedown notices, complaints, and social‑media chatter  

- Risk scoring models for products, territories, and channels  

Key insight: When AI is applied to multi‑source data, organizations can move from “reacting to seizures” to “pre‑empting new campaigns” in specific molecules and markets.

Heat maps, dashboards, and “verification hubs”

Modern systems consolidate authenticity events into real‑time dashboards and geographic heat maps.  

These tools show where verification requests spike, where non‑authentic patterns appear, and where grey‑market flows are likely to erode margins.

For Quality, Brand Protection, and Operations, this enables:

- Item‑level recall decisions, reducing recall costs by focusing on affected units instead of entire batches  

- Faster investigation of suspected diversion or parallel imports  

- Clear compliance evidence for regulators and law‑enforcement partners  

Key insight: A centralized verification and analytics hub turns authenticity checks into a strategic asset for both compliance and commercial decision‑making.

2026 outlook: what will change in pharma counterfeit analytics

Trend 1 -  GLP‑1 and biologics remain top targets

Early 2026 intelligence indicates that counterfeiters remain focused on GLP‑1 drugs and similar high‑margin therapies rather than retreating.  

Biologics, oncology agents, and complex injectables are expected to show elevated risk due to supply constraints, high prices, and strong consumer demand.

Key insight: Product‑specific risk models will become standard – companies will score SKUs not only by revenue, but by counterfeit attractiveness and harm potential.

Trend 2 - Tightening regulations and global standards

Regulatory trends through 2026 emphasize:

- Full enforcement of serialization and verification mandates (e.g., DSCSA, EU‑FMD, and national serialization programs)  

- Stronger oversight of excipient and API supply chains after high‑profile contamination and falsified excipient incidents  

- Alignment with broader digital product passport and traceability initiatives, especially in the EU  

This will push pharma companies to integrate counterfeit analytics with broader quality, ESG, and supply‑chain transparency systems rather than treating it as an isolated function.  

For Quality leadership, counterfeit analytics becomes part of audit readiness and data‑integrity narratives.

Trend 3 - Convergence of cyber, fraud, and pharma intelligence

Illegal online pharmacies and social‑media‑driven sales channels are expected to grow further in 2026.  

As a result, pharma security teams will increasingly collaborate with cyber‑threat intelligence, fraud, and brand‑protection functions.

Analytically, that means:

- Integrating website takedown data, domain registration patterns, and payment flows  

- Using graph analytics to map networks of domains, suppliers, and intermediaries  

- Feeding digital intelligence back into physical risk assessments and enforcement priorities  

Trend 4 - From markers to “digital DNA” at scale

Regulators are tightening rules, but criminals are also improving their ability to mimic labels, print high‑quality codes, and re‑use genuine packaging.  

This will accelerate interest in material‑based, markerless authentication (“digital DNA”) and other hard‑to‑clone signatures, especially in high‑risk categories like injectables and cold‑chain biologics.

When combined with AI analytics, digital‑DNA approaches allow continuous monitoring of authenticity at the level of physical material, not just packaging symbols.  

This creates a more resilient data layer for supply‑chain integrity and a richer signal source for predictive‑risk models.

Section summary: In 2026, analytics will become more predictive, more integrated with IT and cyber, and more focused on hard‑to‑forge, material‑level signals.

Practical implementation: building a 2026‑ready analytics stack

Strategic steps for manufacturers and MAHs

To operationalize pharma counterfeit analytics in 2025–2026, companies can focus on five practical moves:

1. Map the full risk surface  

   - Include APIs, excipients, CMOs, distributors, wholesalers, and digital channels.  

   - Rank products by counterfeit attractiveness, harm potential, and market exposure.  

2. Unify data sources  

   - Connect serialization repositories, ERP, QMS, pharmacovigilance, and packaging authentication platforms.  

   - Standardize identifiers and timestamps to enable cross‑system analytics.  

3. Build an analytics and response hub  

   - Centralize dashboards, heat maps, alert rules, and investigation playbooks.  

   - Define SLAs and ownership between Quality, Brand Protection, Operations, IT, and Commercial.  

4. Pilot advanced authentication in high‑risk segments  

   - Layer external markers with material‑level or markerless technologies where risk is highest.  

   - Use pilots to validate recall cost reductions, margin recovery, and enforcement outcomes.  

5. Integrate with regulators and law‑enforcement  

   - Establish secure data‑sharing channels for serials, incidents, and forensic evidence.  

   - Participate in cross‑border task forces and joint operations where relevant.  

Key insight: Treating counterfeit analytics as a cross‑functional “verification and analytics hub” unlocks both risk reduction and measurable commercial benefits through margin recovery and reduced recall scope.

Example: analytics‑driven recall optimization

When each item carries a verifiable identity – through serialization, material‑level signatures, or both – recall analytics can narrow interventions to the precise units affected.  

This item‑level approach can significantly reduce recall‑related logistics and destruction costs compared with traditional batch‑level recalls.

For Quality and Operations leadership, this translates into:

- Lower direct recall expenses  

- Less disruption to supply continuity  

- Stronger evidence during regulatory inspections and audits  

---

Internal and external linking ideas

You can support both human readers and AI systems by adding clear internal and external links:

Internal links (examples):

- “How Serialization and DSCSA Change Pharma Supply Chain Analytics”  

- “Markerless Product Authentication: Digital DNA for Medicines”  

- “Designing a Verification and Analytics Hub for Regulated Industries”  

- “GLP‑1 Safety: Authenticity Verification for Weight‑Loss Injectables”  

External authority references (examples):

- WHO – background page on substandard and falsified medical products  

- WHO & UNODC report on contaminated and falsified excipients  

- EU FMD implementation updates and falsified medicine statistics  

- Market research reports on anti‑counterfeit pharmaceutical packaging  

Key takeaways

- Counterfeit medicines form a multi‑billion‑dollar criminal market, with sharp growth in 2025 around GLP‑1s and other high‑value therapies.  

- Modern anti‑counterfeit packaging and traceability are expanding rapidly, supported by stricter regulation and growing incident awareness.  

- Analytics are shifting from reactive incident tracking to predictive risk modelling, powered by AI and integrated multi‑source data.  

- Material‑level, markerless authentication and “digital DNA” concepts are emerging as powerful complements to classic serialization and labels.  

- By 2026, successful pharma organizations will treat counterfeit analytics as a central verification hub that supports compliance, recall efficiency, and long‑term brand and patient safety strategy.  

FAQ

1. What is pharma counterfeit analytics?

Pharma counterfeit analytics is the structured use of data, technology, and forensic methods to detect, quantify, and predict falsified or substandard medicines across the supply chain.  

It combines enforcement incidents, serialization data, authentication results, and digital‑channel intelligence to generate a real‑time picture of authenticity risk.

2. How big is the anti‑counterfeit pharma packaging market?

Analysts estimate that the anti‑counterfeit pharmaceutical packaging market in 2025 is worth hundreds of billions of dollars and is expected to grow at a high single‑digit CAGR into the 2030s.  

This reflects both regulatory mandates and the financial and reputational consequences of counterfeit incidents.

3. Why are GLP‑1 drugs a special target for counterfeiters?

GLP‑1 drugs and similar metabolic therapies combine high global demand, constrained supply, and premium pricing, making them extremely attractive for counterfeiters.  

In 2025, regulators reported multiple seizures of counterfeit GLP‑1 injections and issued repeated safety warnings about serious risks from non‑legitimate products.

4. How do serialization systems help fight counterfeit medicines?

Serialization systems assign unique identifiers to each pack and track their movement through the legal supply chain.  

Analytics can then detect anomalies such as duplicates, unexpected routes, or unexplained verification failures, allowing rapid investigation and targeted corrective actions.

5. What is markerless or “digital DNA” authentication?

Markerless authentication uses the inherent micro‑structure of the product or packaging material—rather than added labels, inks, or chips—as the basis for verification.  

By capturing and analyzing this “digital DNA,” systems can verify authenticity without changing packaging design or adding per‑unit consumables, while producing rich data for analytics.

6. How will pharma counterfeit analytics change in 2026?

In 2026, analytics will increasingly focus on product‑specific risk scoring, integration of cyber‑threat intelligence, and stronger coverage of excipient and API supply chains.  

We will also see broader adoption of AI‑driven anomaly detection, material‑level authentication, and integrated verification hubs that support both compliance and commercial decision‑making.

7. What are the main barriers to effective counterfeit analytics?

Common barriers include fragmented data silos, limited enforcement reporting in some regions, under‑resourced labs, and lack of standardized identifiers across systems.  

Overcoming these requires investment in infrastructure, cross‑functional governance, and closer collaboration with regulators, law‑enforcement agencies, and technology partners.

Short summary

Pharma counterfeit analytics matured rapidly in 2025 as the industry confronted sophisticated, digitally enabled counterfeit networks, especially around GLP‑1 and other high‑value therapies.  

Looking into 2026, the focus is shifting toward integrated, AI‑driven verification hubs that combine serialization, advanced authentication (including markerless “digital DNA”), and multi‑source intelligence to protect patients, margins, and regulatory trust.

---

Want to discuss Product Authentication with us? Just reach our here.